Skip to main content

Market Overview

Recap: Eli Lilly Q1 Earnings



Shares of Eli Lilly (NYSE:LLY) fell 5.2% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share rose 6.86% year over year to $1.87, which missed the estimate of $2.14.

Revenue of $6,805,600,000 higher by 16.14% from the same period last year, which missed the estimate of $7,020,000,000.


The upcoming fiscal year's EPS expected to be between $7.80 and $8.00.

The upcoming fiscal year's revenue expected to be between $26,600,000,000 and $27,600,000,000.

How To Listen To The Conference Call

Date: Apr 27, 2021

Time: 09:00 AM

ET Webcast URL:

Price Action

52-week high: $218.00

52-week low: $129.21

Price action over last quarter: down 12.62%

Company Description

Eli Lilly is a drug company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.


Related Articles (LLY)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at